Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance

Dongwei Guo, Gang Zhang, Tadeusz A Wysocki, Beata J. Wysocki, Harris A. Gelbard, Xin Ming Liu, JoEllyn M McMillan, Howard Eliot Gendelman

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Limitations of antiretroviral therapy (ART) include poor patient adherence, drug toxicities, viral resistance, and failure to penetrate viral reservoirs. Recent developments in nanoformulated ART (nanoART) could overcome such limitations. To this end, we now report a novel effect of nanoART that facilitates drug depots within intracellular compartments at or adjacent to the sites of the viral replication cycle. Poloxamer 407-coated nanocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogenization. These drug particles readily accumulated in human monocyte-derived macrophages (MDM). NanoATV concentrations were~1,000 times higher in cells than those that could be achieved by the native drug. ATV particles in late and recycling endosome compartments were seen following pulldown by immunoaffinity chromatography with Rab-specific antibodies conjugated to magnetic beads. Confocal microscopy provided cross validation by immunofluorescent staining of the compartments. Mathematical modeling validated drug-endosomal interactions. Measures of reverse transcriptase activity and HIV-1 p24 levels in culture media and cells showed that such endosomal drug concentrations enhanced antiviral responses up to 1,000-fold. We conclude that late and recycling endosomes can serve as depots for nanoATV. The colocalization of nano- ATV at endosomal sites of viral assembly and its slow release sped antiretroviral activities. Long-acting nanoART can serve as a drug carrier in both cells and subcellular compartments and, as such, can facilitate viral clearance.

Original languageEnglish (US)
Pages (from-to)9504-9513
Number of pages10
JournalJournal of virology
Volume88
Issue number17
DOIs
StatePublished - Jan 1 2014

Fingerprint

drug therapy
HIV
Drug Therapy
drugs
endosomes
Endosomes
Pharmaceutical Preparations
recycling
drug carriers
nanocrystals
drug toxicity
Virus Assembly
Poloxamer
immunoaffinity chromatography
drug interactions
therapeutics
Drug Carriers
RNA-directed DNA polymerase
cells
Patient Compliance

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. / Guo, Dongwei; Zhang, Gang; Wysocki, Tadeusz A; Wysocki, Beata J.; Gelbard, Harris A.; Liu, Xin Ming; McMillan, JoEllyn M; Gendelman, Howard Eliot.

In: Journal of virology, Vol. 88, No. 17, 01.01.2014, p. 9504-9513.

Research output: Contribution to journalArticle

@article{c2c0522068e94f05a5c742841c2aa412,
title = "Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance",
abstract = "Limitations of antiretroviral therapy (ART) include poor patient adherence, drug toxicities, viral resistance, and failure to penetrate viral reservoirs. Recent developments in nanoformulated ART (nanoART) could overcome such limitations. To this end, we now report a novel effect of nanoART that facilitates drug depots within intracellular compartments at or adjacent to the sites of the viral replication cycle. Poloxamer 407-coated nanocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogenization. These drug particles readily accumulated in human monocyte-derived macrophages (MDM). NanoATV concentrations were~1,000 times higher in cells than those that could be achieved by the native drug. ATV particles in late and recycling endosome compartments were seen following pulldown by immunoaffinity chromatography with Rab-specific antibodies conjugated to magnetic beads. Confocal microscopy provided cross validation by immunofluorescent staining of the compartments. Mathematical modeling validated drug-endosomal interactions. Measures of reverse transcriptase activity and HIV-1 p24 levels in culture media and cells showed that such endosomal drug concentrations enhanced antiviral responses up to 1,000-fold. We conclude that late and recycling endosomes can serve as depots for nanoATV. The colocalization of nano- ATV at endosomal sites of viral assembly and its slow release sped antiretroviral activities. Long-acting nanoART can serve as a drug carrier in both cells and subcellular compartments and, as such, can facilitate viral clearance.",
author = "Dongwei Guo and Gang Zhang and Wysocki, {Tadeusz A} and Wysocki, {Beata J.} and Gelbard, {Harris A.} and Liu, {Xin Ming} and McMillan, {JoEllyn M} and Gendelman, {Howard Eliot}",
year = "2014",
month = "1",
day = "1",
doi = "10.1128/JVI.01557-14",
language = "English (US)",
volume = "88",
pages = "9504--9513",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "17",

}

TY - JOUR

T1 - Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance

AU - Guo, Dongwei

AU - Zhang, Gang

AU - Wysocki, Tadeusz A

AU - Wysocki, Beata J.

AU - Gelbard, Harris A.

AU - Liu, Xin Ming

AU - McMillan, JoEllyn M

AU - Gendelman, Howard Eliot

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Limitations of antiretroviral therapy (ART) include poor patient adherence, drug toxicities, viral resistance, and failure to penetrate viral reservoirs. Recent developments in nanoformulated ART (nanoART) could overcome such limitations. To this end, we now report a novel effect of nanoART that facilitates drug depots within intracellular compartments at or adjacent to the sites of the viral replication cycle. Poloxamer 407-coated nanocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogenization. These drug particles readily accumulated in human monocyte-derived macrophages (MDM). NanoATV concentrations were~1,000 times higher in cells than those that could be achieved by the native drug. ATV particles in late and recycling endosome compartments were seen following pulldown by immunoaffinity chromatography with Rab-specific antibodies conjugated to magnetic beads. Confocal microscopy provided cross validation by immunofluorescent staining of the compartments. Mathematical modeling validated drug-endosomal interactions. Measures of reverse transcriptase activity and HIV-1 p24 levels in culture media and cells showed that such endosomal drug concentrations enhanced antiviral responses up to 1,000-fold. We conclude that late and recycling endosomes can serve as depots for nanoATV. The colocalization of nano- ATV at endosomal sites of viral assembly and its slow release sped antiretroviral activities. Long-acting nanoART can serve as a drug carrier in both cells and subcellular compartments and, as such, can facilitate viral clearance.

AB - Limitations of antiretroviral therapy (ART) include poor patient adherence, drug toxicities, viral resistance, and failure to penetrate viral reservoirs. Recent developments in nanoformulated ART (nanoART) could overcome such limitations. To this end, we now report a novel effect of nanoART that facilitates drug depots within intracellular compartments at or adjacent to the sites of the viral replication cycle. Poloxamer 407-coated nanocrystals containing the protease inhibitor atazanavir (ATV) were prepared by high-pressure homogenization. These drug particles readily accumulated in human monocyte-derived macrophages (MDM). NanoATV concentrations were~1,000 times higher in cells than those that could be achieved by the native drug. ATV particles in late and recycling endosome compartments were seen following pulldown by immunoaffinity chromatography with Rab-specific antibodies conjugated to magnetic beads. Confocal microscopy provided cross validation by immunofluorescent staining of the compartments. Mathematical modeling validated drug-endosomal interactions. Measures of reverse transcriptase activity and HIV-1 p24 levels in culture media and cells showed that such endosomal drug concentrations enhanced antiviral responses up to 1,000-fold. We conclude that late and recycling endosomes can serve as depots for nanoATV. The colocalization of nano- ATV at endosomal sites of viral assembly and its slow release sped antiretroviral activities. Long-acting nanoART can serve as a drug carrier in both cells and subcellular compartments and, as such, can facilitate viral clearance.

UR - http://www.scopus.com/inward/record.url?scp=84916900120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916900120&partnerID=8YFLogxK

U2 - 10.1128/JVI.01557-14

DO - 10.1128/JVI.01557-14

M3 - Article

C2 - 24920821

AN - SCOPUS:84916900120

VL - 88

SP - 9504

EP - 9513

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 17

ER -